Endonovo Therapeutics Inc (ENDV)

[Seaheck]

It's my opinion, that at that point (by very early 2018) once heart is FDA approved and the rest of the tests we have going through clinicals right now will have results completed, that we will see a buyout offer come in, somewhere between $2B-$5B, or between $8-$20 per share. There can always be a wild card buyout that exceeds these expectations, but I think $2B will be the bare minimum given the complete coverage of patents that we hold.